Photocure ASA (0IMT) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

All right, well, good afternoon and good morning, depending on where you are in the world. My name is Dan Schneider, President and CEO of PhotoCure, and you're here for the PhotoCure second quarter 2025 results. With me today is Eric Dahl. Just a reminder, the usual disclaimers are in effect for today's presentation. I thought I'd start just kind of reiterating our strategic priorities and initiatives before I get into what I think was a very, very good quarter for PhotoCure. So, you know, first block, accelerate and expand. I think what's important to keep all this in the background of what we've been focused on over the past couple of years. You're delivering on our financial growth, both revenue and EBITDA this year, and continue generating operating leverage. I believe this is our ninth quarter in a row of positive EBITDA, and that leverage continues to build. Driving the PLC mobile strategy in Fortek is doing quite well for the US and is increasingly becoming an important part of our opportunities there. And then for Europe, increasing our penetration in the priority growth markets, Italy, France, UK. And expand our geographic footprint, which we mentioned. In Q2, we now have expanded into Spain. I'll go into that in more detail, but it is one of the larger markets in all of Europe, and it was a market that we were in many years ago when GE had launched back in 2006, 2007. Second block, positioning and access. PLC is positioning to be the primary diagnostic used in precision medicine. That's the way we see it. We see it as the godfather. We're gonna maintain that positioning. It's key to the detection, surveillance, and therapeutic monitoring of these expensive therapies coming onto the market. The high-def technologies are entering the market. We've had upgrade...